Volume 22, Number 2—February 2016
Research
Prognostic Indicators for Ebola Patient Survival
Table 2
Logistic regression models assessing association of patient sex, age, Ct, and time from Ebola virus disease symptom onset to healthcare facility admission with patient survival, Bo District, Sierra Leone, September 2014–January 2015*
Cohort | No. patients |
Unadjusted
|
Adjusted†
|
|||
---|---|---|---|---|---|---|
OR for survival (95% CI) | p value | OR for survival (95% CI) | p value | |||
Primary cohort | ||||||
Male, vs. female | 151 | 0.99 (0.52–1.90) | 0.98 | 0.96 (0.38–2.44) | 0.94 | |
Age, y, increasing, continuous | 151 | 0.97 (0.95–0.99) | 0.009 | 0.97 (0.94–0.99) | 0.01 | |
Age ≥20 y, vs. <20 y | 151 | 0.54 (0.27–1.06) | 0.076 | |||
Ct, decreasing, continuous | 151 | 0.73 (0.65–0.80) | <0.001 | |||
Ct <20, vs. >24 | 151 | 0.0044 (0.0002–0.0245) | <0.001 | 0.003 (0.001–0.018) | <0.001 | |
Ct 20–24, vs. >24 | 151 | 0.12 (0.04–0.28) | <0.001 | 0.086 (0.028–0.22) | <0.001 | |
Ct <24, vs >24 | 151 | 0.04 (0.02–0.10) | <0.001 | |||
Days from symptom onset to admission
to any healthcare facility, increasing,
continuous
|
151
|
0.97 (0.87–1.08)
|
0.59
|
|
0.88 (0.76–1.02)
|
0.089
|
ETU subgroup | ||||||
Days from symptom onset to admission
to ETU, increasing, continuous
|
99
|
0.95 (0.83–1.07)
|
0.37
|
|
0.88 (0.74–1.03)
|
0.11
|
Final 2 months subgroup | ||||||
Days from symptom onset to admission to isolation ward, increasing, continuous | 68 | 0.98 (0.79–1.20) | 0.84 | 0.85 (0.64–1.11) | 0.23 |
*Ct, cycle threshold; ETU, Ebola treatment unit; OR, odds ratio.
†Adjusted for sex, age (continuous), and Ct (<20, 20–24, >24).
1These authors contributed equally to this article.
Page created: January 14, 2016
Page updated: January 14, 2016
Page reviewed: January 14, 2016
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.